MedTrace Logo

Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)

NCT02001181 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2015-10-15

Study results available
· View outcomes & findings →

Summary

The study is being conducted to evaluate the efficacy, safety and tolerability of 2% tofacitinib ointment (20 mg/g) BID (twice daily) in subjects with mild to moderate atopic dermatitis compared to placebo (vehicle) BID for 4 weeks.

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

Tofacitinib ointment 20mg/g

Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks

DRUG

Placebo ointment (Vehicle)

Placebo ointment (vehicle) twice daily (BID) for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02001181 on ClinicalTrials.gov